Gradiant Announces World's First Fully Integrated Lithium Production Facility from Oilfield Produced Water
Boston, United States:
Pennsylvania Plant to Begin Commercial Production of Battery-Grade Lithium by Early 2026;
Long-term offtake agreement secured with U.S. battery manufacturer
Gradiant, a global leader in advanced water and resource recovery, announced today that its lithium business, alkaLi, will design, build, own, and operate a commercial lithium production facility in the Marcellus Shale Formation of Pennsylvania. This site is the world's first to Extract, Concentrate, and Convert (EC²) lithium in a fully integrated, end-to-end process from oilfield produced water.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250624673369/en/
alkaLi's commercial lithium production facility in the Marcellus Shale Formation of Pennsylvania is the world's first to Extract, Concentrate, and Convert (EC²) lithium in a fully integrated, end-to-end process from oilfield produced water.
This announcement builds on last year's launch of alkaLi's EC² platform, which guarantees a minimum 95% lithium recovery at customer sites—empowering producers to deliver battery-grade lithium carbonate faster, cheaper, and more sustainably.
Gradiant's alkaLi owns and operates the Pennsylvania facility—including equipment, land, water and mineral rights, and permits. This vertically integrated model secures long-term U.S. lithium supply while avoiding the permitting and ownership delays that often stall critical mineral projects.
Currently in testing, the system has already proven key benchmarks: 97% lithium recovery from produced water and 99.5% purity for battery-grade lithium carbonate. Full commercial operations are on track for early 2026.
In a major commercial achievement, alkaLi has signed a multi-year offtake agreement to supply up to 5,000 metric tonnes annually of battery-grade lithium carbonate to a U.S. lithium-ion battery manufacturer for electric vehicles (EVs) and energy storage systems (ESS). The deal affirms strong market demand and the commercial readiness of alkaLi's solution.
alkaLi offers multiple models for partners and customers: Deploy the EC² solution to lithium producers
Design, build and operate integrated systems for partners
Produce and sell lithium from alkaLi-owned assets
'We now have a fully operational lithium production asset in the U.S. that proves what EC² can deliver,' said Anurag Bajpayee, CEO of Gradiant. 'This isn't a concept—it's a live facility demonstrating that clean, domestic lithium production is both viable and scalable. Our goal isn't to compete with customers, but to empower them—and the broader industry—to meet surging demand for battery-grade lithium and accelerate the clean energy transition. This strategic investment in the Marcellus Shale, which could supply 50% of U.S. lithium demand, validates the maturity of alkaLi's technology and secures a long-term domestic supply.'
alkaLi's patented EC² process combines Direct Lithium Extraction (DLE), concentration, and final conversion into a single streamlined system. Compared to conventional methods, EC² offers: Up to 50% lower capital and operating costs
Modular, pre-engineered systems for rapid global deployment
AI-optimized performance for real-time control and predictive maintenance
Reduced environmental footprint and streamlined permitting
Feedwater flexibility – including geothermal brines, battery recycling, and produced water sources
Gradiant invites prospective customers, partners, and investors to connect with alkaLi to explore how this breakthrough platform can accelerate the global transition to clean energy.
About alkaLi
alkaLi is pioneering the future of critical mineral recovery to power the clean energy transition. A spin-out of Gradiant and headquartered in Boston, alkaLi combines deep expertise in advanced water and wastewater treatment with next-generation innovation in mineral extraction. Its breakthrough EC² solution enables efficient, sustainable, and cost-effective production of battery-grade lithium and other essential elements. Backed by significant investment and a proven track record, alkaLi is at the forefront of revolutionizing critical mineral supply for a sustainable future. Learn more at alkaLi3.com
About Gradiant
Gradiant is a Different Kind of Water Company. With a full suite of differentiated and proprietary end-to-end solutions for advanced water and wastewater treatment powered by the top minds in water, the company serves its clients' mission-critical operations in the world's essential industries, including semiconductors, pharmaceuticals, food & beverage, lithium and critical minerals, and renewable energy. Gradiant's innovative solutions reduce water used and wastewater discharged, reclaim valuable resources, and renew wastewater into freshwater. The Boston-headquartered company was founded at MIT and has over 1,400 employees worldwide. Learn more at gradiant.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250624673369/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
ZOWIE Unveils First European Esports Lab
EINDHOVEN, Netherlands--(BUSINESS WIRE)--ZOWIE, the leading esports-focused brand of BenQ Corporation, proudly announces the establishment of its first European Sports Science Lab in Eindhoven. As the third lab in ZOWIE's global network, this new facility underscores the brand's commitment to applying sports science to esports peripheral design, now with strategic emphasis on Europe's burgeoning competitive scene. ZOWIE is taking a truly scientific approach to helping European pros reach their peak. This is not just about equipment—it's about understanding performance at its deepest level. "With the ZOWIE Sports Science Lab, we're bringing scientific methodology to help European pro players unlock their full potential,' said Jay Wu, President of BenQ Europe B.V. 'Every design is grounded in real-world player data and expert insights, reflecting our dedication to performance-driven product innovation and the future of esports.' Leveraging motion capture and electromyography (EMG), the lab analyzes player interactions with mice, collecting data on ergonomics, joint angles, movement speed, and muscle activity. This enables personalized mouse recommendations tailored to individual playstyles and game types, letting players optimize their training based on fatigue data to maintain peak performance under prolonged competitive pressure. Player-Centric Design, Informed by Data Since the launch of the iconic EC series mouse, co-developed in 2010 with Swedish esports legend Emil 'HeatoN' Christensen, ZOWIE has remained committed to evolving its products through real-world player feedback. With the new Sports Science Lab, ZOWIE can assess how various mouse models align with individual gameplay styles across titles like CS2, VALORANT, Fortnite, and Apex Legends, enabling precise equipment recommendations that maximize player potential. The lab also evaluates performance before and after fatigue sets in, helping players identify issues like reduced finger stability or imprecise deceleration control, and adapt their training accordingly. Continuous collaboration with esports athletes throughout the testing process ensures that every product generation reflects the evolving demands of actual competition. Sports Science in Action: ZOWIE Mouse Design Sports science insights play a central role in shaping ZOWIE's mouse designs. The U series, for instance, was designed for fast-paced games like Valorant, Fortnite, and Apex Legends, featuring a lightweight wireless build and improved claw grip feel to enhance agility and endurance. Similarly, the EC3 goes beyond simply scaling down from EC2 to incorporate deeper sports science insights, with a restructured design that adjusts finger joint angles and side button placement to reduce fatigue during rapid clicking and avoid accidental presses. Testing has shown that these refinements help minimize strain in the wrist flexor muscles during repeated click-intensive tasks. The DW series, ZOWIE's latest symmetrical wireless mouse, was also developed based on real-world gameplay needs and professional player testing data. Designed to support a variety of grip styles, each model in the DW series offers distinct gameplay advantages. For example, DW-FK variants excel during repeated micro-adjustments, providing greater precision and long-term comfort in FPS games that require strong aiming. Looking Ahead: Expanding Innovation Through Research ZOWIE has long been devoted to innovating esports technology, holding numerous patents and continually evolving its product design philosophy. The launch of the new European Sports Science Lab marks a milestone in ZOWIE's product innovation journey. With the European esports market experiencing exponential growth – projected to reach USD 4.3 billion by 2033 with a CAGR of 11.04% from 2025 to 2033 1 – ZOWIE is committed to expanding its research efforts to deliver tailored gear and training recommendations that adapt to the evolving demands of players. About ZOWIE / BenQ Corporation Established in 2008, ZOWIE is a top esports brand for professional players, focusing on player-centric design and dedicated to providing esports gear for professional FPS players. In 2015, ZOWIE joined BenQ Corporation, combining its expertise with BenQ's robust R&D resources and leading panel manufacturing capabilities. ZOWIE remains committed to driving excellence in product design through scientific research. With 70% of professional players using ZOWIE products, the brand continues to successfully deliver serious gear technology to global players. For more information, please visit:
Business Upturn
4 days ago
- Business Upturn
Gradiant Announces World's First Fully Integrated Lithium Production Facility from Oilfield Produced Water
Boston, United States: Pennsylvania Plant to Begin Commercial Production of Battery-Grade Lithium by Early 2026; Long-term offtake agreement secured with U.S. battery manufacturer Gradiant, a global leader in advanced water and resource recovery, announced today that its lithium business, alkaLi, will design, build, own, and operate a commercial lithium production facility in the Marcellus Shale Formation of Pennsylvania. This site is the world's first to Extract, Concentrate, and Convert (EC²) lithium in a fully integrated, end-to-end process from oilfield produced water. This press release features multimedia. View the full release here: alkaLi's commercial lithium production facility in the Marcellus Shale Formation of Pennsylvania is the world's first to Extract, Concentrate, and Convert (EC²) lithium in a fully integrated, end-to-end process from oilfield produced water. This announcement builds on last year's launch of alkaLi's EC² platform, which guarantees a minimum 95% lithium recovery at customer sites—empowering producers to deliver battery-grade lithium carbonate faster, cheaper, and more sustainably. Gradiant's alkaLi owns and operates the Pennsylvania facility—including equipment, land, water and mineral rights, and permits. This vertically integrated model secures long-term U.S. lithium supply while avoiding the permitting and ownership delays that often stall critical mineral projects. Currently in testing, the system has already proven key benchmarks: 97% lithium recovery from produced water and 99.5% purity for battery-grade lithium carbonate. Full commercial operations are on track for early 2026. In a major commercial achievement, alkaLi has signed a multi-year offtake agreement to supply up to 5,000 metric tonnes annually of battery-grade lithium carbonate to a U.S. lithium-ion battery manufacturer for electric vehicles (EVs) and energy storage systems (ESS). The deal affirms strong market demand and the commercial readiness of alkaLi's solution. alkaLi offers multiple models for partners and customers: Deploy the EC² solution to lithium producers Design, build and operate integrated systems for partners Produce and sell lithium from alkaLi-owned assets 'We now have a fully operational lithium production asset in the U.S. that proves what EC² can deliver,' said Anurag Bajpayee, CEO of Gradiant. 'This isn't a concept—it's a live facility demonstrating that clean, domestic lithium production is both viable and scalable. Our goal isn't to compete with customers, but to empower them—and the broader industry—to meet surging demand for battery-grade lithium and accelerate the clean energy transition. This strategic investment in the Marcellus Shale, which could supply 50% of U.S. lithium demand, validates the maturity of alkaLi's technology and secures a long-term domestic supply.' alkaLi's patented EC² process combines Direct Lithium Extraction (DLE), concentration, and final conversion into a single streamlined system. Compared to conventional methods, EC² offers: Up to 50% lower capital and operating costs Modular, pre-engineered systems for rapid global deployment AI-optimized performance for real-time control and predictive maintenance Reduced environmental footprint and streamlined permitting Feedwater flexibility – including geothermal brines, battery recycling, and produced water sources Gradiant invites prospective customers, partners, and investors to connect with alkaLi to explore how this breakthrough platform can accelerate the global transition to clean energy. About alkaLi alkaLi is pioneering the future of critical mineral recovery to power the clean energy transition. A spin-out of Gradiant and headquartered in Boston, alkaLi combines deep expertise in advanced water and wastewater treatment with next-generation innovation in mineral extraction. Its breakthrough EC² solution enables efficient, sustainable, and cost-effective production of battery-grade lithium and other essential elements. Backed by significant investment and a proven track record, alkaLi is at the forefront of revolutionizing critical mineral supply for a sustainable future. Learn more at About Gradiant Gradiant is a Different Kind of Water Company. With a full suite of differentiated and proprietary end-to-end solutions for advanced water and wastewater treatment powered by the top minds in water, the company serves its clients' mission-critical operations in the world's essential industries, including semiconductors, pharmaceuticals, food & beverage, lithium and critical minerals, and renewable energy. Gradiant's innovative solutions reduce water used and wastewater discharged, reclaim valuable resources, and renew wastewater into freshwater. The Boston-headquartered company was founded at MIT and has over 1,400 employees worldwide. Learn more at View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
4 days ago
- Yahoo
Argenx Secures EC Approval for Subcutaneous VYVGART in CIDP Treatment
Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European Commission/EC approved VYVGART (efgartigimod alfa) 1000mg for subcutaneous/SC injection. The approval is for its use as a monotherapy in adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy/CIDP who have previously been treated with corticosteroids or immunoglobulins. VYVGART SC is available as a vial or prefilled syringe and offers a flexible administration option, which allows it to be given by a patient, caregiver, or healthcare professional. Treatment begins with a weekly dose regimen, which can be adjusted to every other week based on clinical evaluation. This marks the first approval of an IgG Fc-antibody fragment specifically targeting the neonatal Fc receptor (FcRn) for CIDP in Europe, and it represents the first novel mechanism of action for CIDP treatment in 30+ years. A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases. The EC's decision follows a positive recommendation from the Committee for Medicinal Products for Human Use/CHMP and is supported by the results of the ADHERE clinical trial, which is the largest study conducted to date on CIDP patients. CIDP is a rare, debilitating, and often progressive immune-mediated neuromuscular disorder affecting the peripheral nervous system. The EC approval covers all 27 European Union Member States, as well as Iceland, Liechtenstein, and Norway. Argenx (NASDAQ:ARGX) is a commercial-stage biopharma company that develops various therapies for the treatment of autoimmune diseases in the US, Japan, China, the Netherlands, and internationally. While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
